• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

12001-79-5 (VITAMIN K1)

1

Identification

VITAMIN K1 VITAMIN K1
Name VITAMIN K1
Formula C31H46O2
MW 450.7
CAS No. 12001-79-5
EINECS 201-564-2
Smiles O=C(C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C1C)C2=CC=CC=C2C1=O
Synonyms VITAMIN K;Synkavite;2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione;VITAMIN K1 USP23;Vitamin K substances;C01628
InChI InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+
2

Introduction

Vitamin K is a group of fat soluble vitamins, important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.

Background Information

Vitamin K is a group of fat soluble vitamins, important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000104587

Storage condition

Solubility

DMSO by CHEMSCENE, LLC
DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways Others
Target Others
Research Area Cardiovascular Disease
Indications Healthy Folliculitis Aging|Osteoporosis Thrombosis Aortic Valve Calcification End Stage Renal Failure on Dialysis|Atrial Fibrillation Cardiovascular Diseases Thrombosis Coagulation|Bleeding|Thrombosis Arterial Stiffness|Vitamin K2 Deficiency Vascular Calcification Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|Diabetes Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular Diseases Calciphylaxis|Calcific Uremic Arteriolopathy Orthostatic Hypotension Endstage Kidney Disease Kidney Diseases|Coronary Artery Calcification Vitamin K-Status Obesity|Insulin Resistance|Insulin Sensitivity|Beta-Cell Dysfunction|Prediabetes Aortic Valve Stenosis|Bicuspid Aortic Valve Carboxylation Level|Vitamin K-dependent Proteins Coronary Artery Disease Supplementation|Bone Health|Crohn's Disease Coagulation Vitamin K Supplementation|Endstage Renal Disease|Cardiovascular Disease|Bone Disease Post-Menopausal Osteoporosis|Post-Menopausal Osteopenia Anticoagulants|Warfarin Osteoporosis|Vascular Calcification|Inflammation Coagulation|Bleeding|Thrombosis Carotid Disease|Atherosclerosis Relapsing-Remitting Multiple Sclerosis Dysmenorrhea|Pain, Menstrual Healthy Dysmenorrhea Vascular Calcification Carotid Plaques Bone Health|Vascular Health Atrial Fibrillation Blood Coagulation Disorders Rheumatic Heart Disease Bone Density|Overweight Atrial Fibrillation Atrial Fibrillation|Percutaneous Coronary Intervention Atrial Fibrillation Atrial Fibrillation Atrial Fibrillation Ecchymosis Atrial Fibrillation Osteoporosis Thrombosis Atrial Fibrillation Atrial Fibrillation Atrial Fibrillation Cervical Artery Dissection Acute Coronary Syndromes Osteoporosis Atrial Fibrillation Atrial Fibrillation and Flutter Atrial Fibrillation (Prevention of Stroke) Atrial Fibrillation Venous Thromboembolism|Neoplasms Kidney Failure, Chronic Pharmacokinetics Atrial Fibrillation Venous Thrombosis Deep Vein Thrombosis|Pulmonary Embolism Venous Thromboembolism Venous Thrombosis|Deep Vein Thrombosis Deep Vein Thrombosis Alzheimer Disease Arthritis, Rheumatoid Neoplasms Solid Tumors Relapsing-Remitting Multiple Sclerosis Stable Angina|Unstable Angina|STEMI|NSTEMI|Coronary Disease Healthy Healthy Healthy Healthy
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
VITAMIN K1 Maastricht University Medical Center Healthy 2009/4/1
VITAMIN K1 Per Pfeiffer|Odense University Hospital Folliculitis 2010/5/1 Phase 2
VITAMIN K1 Tufts University Aging|Osteoporosis 2006/5/1
VITAMIN K1 Stephan Moll, MD|University of North Carolina, Chapel Hill Thrombosis 2009/11/1
VITAMIN K1 RWTH Aachen University Aortic Valve Calcification 2010/1/1 Phase 3
VITAMIN K1 University Health Network, Toronto End Stage Renal Failure on Dialysis|Atrial Fibrillation 2014/1/1 Phase 2
VITAMIN K1 RWTH Aachen University Cardiovascular Diseases 2013/10/1 Phase 3
VITAMIN K1 Danisco Thrombosis 2012/2/1 Phase 2
VITAMIN K1 St. Joseph's Healthcare Hamilton|McMaster University|University of Western Ontario, Canada Coagulation|Bleeding|Thrombosis 2010/7/1 Phase 3
VITAMIN K1 Lebanese American University|Omicron Pharmaceuticals Arterial Stiffness|Vitamin K2 Deficiency 2015/3/1 Phase 2
VITAMIN K1 Rogier Caluwe|Onze Lieve Vrouw Hospital Vascular Calcification 2011/5/1 Phase 3
VITAMIN K1 Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|Diabetes 2013/9/1 Phase 1|Phase 2
VITAMIN K1 Augusta University Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular Diseases 2016/10/1 Phase 1|Phase 2
VITAMIN K1 Massachusetts General Hospital|National Kidney Foundation Calciphylaxis|Calcific Uremic Arteriolopathy 2015/3/1
VITAMIN K1 University of Dundee|British Geriatrics Society Orthostatic Hypotension 2012/4/1
VITAMIN K1 Dr. Rachel Holden|Kingston General Hospital|Clinical Evaluation Research Unit at Kingston General Hospital Endstage Kidney Disease 2012/11/1 Phase 2
VITAMIN K1 Medical Universtity of Lodz Kidney Diseases|Coronary Artery Calcification 2009/6/1 Phase 4
VITAMIN K1 Maastricht University Medical Center Vitamin K-Status 2007/5/1
VITAMIN K1 Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA Obesity|Insulin Resistance|Insulin Sensitivity|Beta-Cell Dysfunction|Prediabetes 2015/2/1 Phase 1|Phase 2
VITAMIN K1 Maastricht University Medical Center Aortic Valve Stenosis|Bicuspid Aortic Valve 2016/8/1 Phase 2
VITAMIN K1 Maastricht University Medical Center Carboxylation Level|Vitamin K-dependent Proteins 2009/10/1
VITAMIN K1 Maastricht University Medical Center|VitaK Coronary Artery Disease 2011/10/1
VITAMIN K1 University College Cork|Health Research Board, Ireland Supplementation|Bone Health|Crohn's Disease 2008/7/1 Phase 4
VITAMIN K1 Ottawa Hospital Research Institute Coagulation 2008/11/1 Phase 3
VITAMIN K1 Zealand University Hospital Vitamin K Supplementation|Endstage Renal Disease|Cardiovascular Disease|Bone Disease 2016/11/1 Phase 2|Phase 3
VITAMIN K1 University Health Network, Toronto|Canadian Institutes of Health Research (CIHR) Post-Menopausal Osteoporosis|Post-Menopausal Osteopenia 2002/1/1 Phase 3
VITAMIN K1 University of North Carolina, Chapel Hill Anticoagulants|Warfarin 2005/10/1
VITAMIN K1 National Institute on Aging (NIA)|National Heart, Lung, and Blood Institute (NHLBI)|Arthritis Foundation|USDA Beltsville Human Nutrition Research Center Osteoporosis|Vascular Calcification|Inflammation 2001/10/1 Phase 3
VITAMIN K1 St. Joseph's Healthcare Hamilton|McMaster University Coagulation|Bleeding|Thrombosis 2004/9/1 Phase 3
VITAMIN K1 Azienda Ospedaliera Sant'Anna Carotid Disease|Atherosclerosis 2013/9/1 Phase 2
VITAMIN K1 Biogen Relapsing-Remitting Multiple Sclerosis 2017/3/10 Phase 4
VITAMIN K1 University of California, San Francisco Dysmenorrhea|Pain, Menstrual 2009/10/1
VITAMIN K1 Maastricht University Medical Center Healthy 2008/6/1
VITAMIN K1 National Center for Complementary and Integrative Health (NCCIH) Dysmenorrhea 2004/9/1 Phase 1
VITAMIN K1 Onze Lieve Vrouw Hospital Vascular Calcification 2015/11/1 Phase 4
VITAMIN K1 Scientific Institute San Raffaele Carotid Plaques 2016/11/1
VITAMIN K1 Maastricht University Medical Center Bone Health|Vascular Health 2011/3/1
VITAMIN K1 Assistance Publique - Hôpitaux de Paris Atrial Fibrillation 2015/2/1
VITAMIN K1 Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico Blood Coagulation Disorders 2006/8/1
VITAMIN K1 Population Health Research Institute|University of Cape Town Rheumatic Heart Disease 2016/7/1 Phase 3
VITAMIN K1 Oslo University Hospital|Norwegian Foundation for Health and Rehabilitation Bone Density|Overweight 2003/8/1
VITAMIN K1 Bayer Atrial Fibrillation 2016/2/12
VITAMIN K1 Janssen Scientific Affairs, LLC|Bayer Atrial Fibrillation|Percutaneous Coronary Intervention 2013/5/1 Phase 3
VITAMIN K1 Bayer|Janssen Research & Development, LLC Atrial Fibrillation 2015/10/1
VITAMIN K1 Boehringer Ingelheim Atrial Fibrillation 2016/6/20
VITAMIN K1 German Atrial Fibrillation Network|Bristol-Myers Squibb|Pfizer|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Atrial Fibrillation 2014/12/1 Phase 4
VITAMIN K1 Northwestern University Ecchymosis 2006/7/1
VITAMIN K1 Bayer Atrial Fibrillation 2016/2/12
VITAMIN K1 TNO Osteoporosis 2008/11/1
VITAMIN K1 Bristol-Myers Squibb|Pediatric Heart Network|Pfizer Thrombosis 2017/1/4 Phase 2
VITAMIN K1 Bayer|Janssen Research & Development, LLC Atrial Fibrillation 2012/10/1 Phase 3
VITAMIN K1 Janssen Scientific Affairs, LLC|Bayer Atrial Fibrillation 2013/2/1 Phase 3
VITAMIN K1 Pfizer|Bristol-Myers Squibb Atrial Fibrillation 2014/7/1 Phase 4
VITAMIN K1 University Hospital, Basel, Switzerland|University Hospital Inselspital, Berne|University of Lausanne Hospitals Cervical Artery Dissection 2013/9/1 Phase 4
VITAMIN K1 Bristol-Myers Squibb|Pfizer|Duke Clinical Research Institute Acute Coronary Syndromes 2015/6/4 Phase 4
VITAMIN K1 Eisai Limited|Eisai Inc. Osteoporosis 2002/2/1 Phase 4
VITAMIN K1 Sanofi Atrial Fibrillation 2003/9/1 Phase 3
VITAMIN K1 Vivencio Barrios|Bayer|Hospital Universitario Ramon y Cajal Atrial Fibrillation and Flutter 2014/2/1
VITAMIN K1 Bayer|Janssen, LP Atrial Fibrillation (Prevention of Stroke) 2015/5/1
VITAMIN K1 Bayer|Janssen Research & Development, LLC Atrial Fibrillation 2016/2/12
VITAMIN K1 University Medical Center Groningen Venous Thromboembolism|Neoplasms 2010/8/1 Phase 3
VITAMIN K1 University Hospital, Strasbourg, France Kidney Failure, Chronic 2017/1/1 Phase 4
VITAMIN K1 University of North Carolina, Chapel Hill Pharmacokinetics 2007/1/1
VITAMIN K1 Bayer|Janssen Scientific Affairs, LLC Atrial Fibrillation 2016/9/8
VITAMIN K1 Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Venous Thrombosis 2008/11/1 Phase 1
VITAMIN K1 St. Orsola Hospital Deep Vein Thrombosis|Pulmonary Embolism 2002/9/1 Phase 4
VITAMIN K1 Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Venous Thromboembolism 2004/12/1 Phase 2
VITAMIN K1 Bayer Venous Thrombosis|Deep Vein Thrombosis 2004/3/1 Phase 2
VITAMIN K1 Sanofi Deep Vein Thrombosis 2003/5/1 Phase 3
VITAMIN K1 Bristol-Myers Squibb Alzheimer Disease 2008/8/1 Phase 1
VITAMIN K1 Janssen Research & Development, LLC Arthritis, Rheumatoid 2012/10/11 Phase 1
VITAMIN K1 Clovis Oncology, Inc. Neoplasms 2016/3/1 Phase 1
VITAMIN K1 Daiichi Sankyo Inc.|Medpace, Inc. Solid Tumors 2011/12/1 Phase 1
VITAMIN K1 Biogen Relapsing-Remitting Multiple Sclerosis 2011/11/1 Phase 3
VITAMIN K1 IHF GmbH - Institut für Herzinfarktforschung|OrbusNeich Stable Angina|Unstable Angina|STEMI|NSTEMI|Coronary Disease 2016/4/1 Phase 4
VITAMIN K1 Janssen Research & Development, LLC|Bayer Healthy 2011/10/1 Phase 1
VITAMIN K1 Boehringer Ingelheim Healthy 2005/9/1 Phase 1
VITAMIN K1 Boehringer Ingelheim Healthy 2008/6/1 Phase 1
VITAMIN K1 Boehringer Ingelheim Healthy 2006/1/1 Phase 1
7

Safety Data of VITAMIN K1

RTECS : QJ5800000
WGKGermany : 2
8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Alfa Chemistry USA
Biochempartner Co., Ltd China
CHEMSCENE, LLC 50mg/USD60();100mg/USD84() USA
MedChemexpress Co., Ltd. 50mg/USD60();100mg/USD84() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 50mg/USD60();100mg/USD84() China
10

Related Products

Other Forms of 12001-79-5

Name CAS No Formula MW

Recommended Compounds in Others

Name CAS No Formula MW
(R)-(+)-Etomoxir (sodium salt) 828934-41-4 C15H18ClNaO4 320.74
Dictamine 484-29-7 C12H9NO2 199.21
3,3',5-Triiodo-L-thyronine (sodium) 55-06-1 C15H11I3NNaO4 672.9553
Fabomotizole (hydrochloride) 173352-39-1 C15H22ClN3O2S 343.8721
FPH2 957485-64-2 C14H16ClN5O2S 353.83
α-Tocopherol (phosphate) 38976-17-9 C29H51O5P 510.69
BAMB-4 891025-25-5 C15H12N2O2 252.27
LDN-27219 312946-37-5 C20H16N4O2S2 408.5
ISO-1 478336-92-4 C12H13NO4 235.24
Aurothioglucose 12192-57-3 C6H11AuO5S 392.18
Oxybenzone 131-57-7 C14H12O3 228.24
ITX3 347323-96-0 C22H17N3OS 371.45
Cardiogreen 3599-32-4 C43H47N2NaO6S2 774.96
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 465.34
INH1 313553-47-8 C18H16N2OS 308.4
PF6-AM 1268491-69-5 C33H31BO12 630.4
XEN445 1515856-92-4 C18H17F3N2O3 366.33
Disperse Blue 148 52239-04-0 C19H19N5O4S 413.45026
Solvent Blue 35 17354-14-2 C22H26N2O2 350.454
CID-797718 370586-05-3 C12H11NO3 217.2206

Recommended Compounds in Same Indication

Name CAS No Formula MW
Vernakalant 794466-70-9 C20H31NO4 349.46
Dabigatran etexilate (mesylate) 872728-81-9 C35H45N7O8S 723.84
MSX-122 897657-95-3 C16H16N6 292.34
Toremifene (Citrate) 89778-27-8 C32H36ClNO8 598.08
Alfacalcidol 41294-56-8 C27H44O2 400.64
Colchicine 64-86-8 C22H25NO6 399.44
VGX-1027 6501-72-0 C11H11NO3 205.21
5-R-Rivaroxaban 865479-71-6 C19H18ClN3O5S 435.88
Vernakalant (Hydrochloride) 748810-28-8 C20H32ClNO4 385.93
Choline Fenofibrate 856676-23-8 C22H28ClNO5 421.91
AZD1981 802904-66-1 C19H17ClN2O3S 388.87
Rivaroxaban 366789-02-8 C19H18ClN3O5S 435.88
4-Thiazolidinone, 5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylene]-3-(2-methylphenyl)-2-(propylimino)-, (2Z,5Z)- 854107-55-4 C22H23ClN2O4S 446.95
Edoxaban 480449-70-5 C24H30ClN7O4S 548.06
Edoxaban (tosylate) 480449-71-6 C31H38ClN7O7S2 720.26
Apixaban 503612-47-3 C25H25N5O4 459.5
Odanacatib 603139-19-1 C25H27F4N3O3S 525.56
MK-0773 606101-58-0 C27H34FN5O2 479.59
RSV604 676128-63-5 C22H17FN4O2 388.39
Varespladib 172732-68-2 C21H20N2O5 380.39
11

Route of Synthesis

12

References

13

More Information

VITAMIN K1

Tags: buy 12001-79-5 IC50 | 12001-79-5 price | 12001-79-5 cost | 12001-79-5 solubility | 12001-79-5 purchase | 12001-79-5 manufacturer | 12001-79-5 research buy | 12001-79-5 order | 12001-79-5 MSDS | 12001-79-5 chemical structure | 12001-79-5 Storage condition | 12001-79-5 molecular weight | 12001-79-5 mw | 12001-79-5 datasheet | 12001-79-5 supplier | 12001-79-5 cell line | 12001-79-5 NMR | 12001-79-5 MS | 12001-79-5 IR | 12001-79-5 solubility | 12001-79-5 Safe information | 12001-79-5 Qc and Spectral Information | 12001-79-5 Clinical Information | 12001-79-5 Clinical Trial | 12001-79-5 Route of Synthesis | 12001-79-5 storage condition | 12001-79-5 diseases and conditions | 12001-79-5 flash point | 12001-79-5 boiling point | 12001-79-5 melting point | 12001-79-5 storage condition | 12001-79-5 brand